Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More
CADILA HEALTHCARE | STERLING BIOTECH | CADILA HEALTHCARE/ STERLING BIOTECH |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 28.2 | -0.4 | - | View Chart |
P/BV | x | 4.5 | 0.0 | 31,873.4% | View Chart |
Dividend Yield | % | 0.8 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
STERLING BIOTECH Dec-13 |
CADILA HEALTHCARE/ STERLING BIOTECH |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 11 | 3,355.2% | |
Low | Rs | 207 | 3 | 6,073.5% | |
Sales per share (Unadj.) | Rs | 139.2 | 26.8 | 519.4% | |
Earnings per share (Unadj.) | Rs | 11.8 | -15.0 | -78.7% | |
Cash flow per share (Unadj.) | Rs | 18.6 | -5.5 | -339.9% | |
Dividends per share (Unadj.) | Rs | 3.50 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 101.4 | 54.9 | 184.7% | |
Shares outstanding (eoy) | m | 1,023.74 | 267.87 | 382.2% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.0 | 0.3 | 774.0% | |
Avg P/E ratio | x | 23.7 | -0.5 | -5,110.9% | |
P/CF ratio (eoy) | x | 15.0 | -1.3 | -1,182.7% | |
Price / Book Value ratio | x | 2.8 | 0.1 | 2,176.9% | |
Dividend payout | % | 29.8 | 0 | - | |
Avg Mkt Cap | Rs m | 286,033 | 1,862 | 15,364.1% | |
No. of employees | `000 | 13.4 | 1.4 | 990.0% | |
Total wages/salary | Rs m | 24,145 | 547 | 4,415.7% | |
Avg. sales/employee | Rs Th | 10,632.7 | 5,303.3 | 200.5% | |
Avg. wages/employee | Rs Th | 1,801.2 | 403.8 | 446.0% | |
Avg. net profit/employee | Rs Th | 898.5 | -2,959.0 | -30.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 7,181 | 1,984.9% | |
Other income | Rs m | 1,139 | 43 | 2,673.7% | |
Total revenues | Rs m | 143,670 | 7,223 | 1,989.0% | |
Gross profit | Rs m | 24,198 | 947 | 2,555.5% | |
Depreciation | Rs m | 6,965 | 2,543 | 273.9% | |
Interest | Rs m | 3,418 | 4,377 | 78.1% | |
Profit before tax | Rs m | 14,954 | -5,931 | -252.1% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | -1,924 | -166.2% | |
Profit after tax | Rs m | 12,044 | -4,007 | -300.6% | |
Gross profit margin | % | 17.0 | 13.2 | 128.7% | |
Effective tax rate | % | 21.4 | 32.4 | 65.9% | |
Net profit margin | % | 8.5 | -55.8 | -15.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 14,335 | 608.0% | |
Current liabilities | Rs m | 82,694 | 49,809 | 166.0% | |
Net working cap to sales | % | 3.1 | -494.0 | -0.6% | |
Current ratio | x | 1.1 | 0.3 | 366.2% | |
Inventory Days | Days | 71 | 403 | 17.7% | |
Debtors Days | Days | 94 | 171 | 55.0% | |
Net fixed assets | Rs m | 133,236 | 55,432 | 240.4% | |
Share capital | Rs m | 1,024 | 268 | 382.2% | |
"Free" reserves | Rs m | 102,733 | 13,935 | 737.2% | |
Net worth | Rs m | 103,757 | 14,701 | 705.8% | |
Long term debt | Rs m | 32,146 | 9,478 | 339.2% | |
Total assets | Rs m | 236,866 | 73,988 | 320.1% | |
Interest coverage | x | 5.4 | -0.4 | -1,514.3% | |
Debt to equity ratio | x | 0.3 | 0.6 | 48.1% | |
Sales to assets ratio | x | 0.6 | 0.1 | 620.0% | |
Return on assets | % | 6.5 | 0.5 | 1,303.2% | |
Return on equity | % | 11.6 | -27.3 | -42.6% | |
Return on capital | % | 13.7 | -6.4 | -213.7% | |
Exports to sales | % | 0 | 25.9 | 0.0% | |
Imports to sales | % | 0 | 0.2 | 0.0% | |
Exports (fob) | Rs m | NA | 1,860 | 0.0% | |
Imports (cif) | Rs m | NA | 12 | 0.0% | |
Fx inflow | Rs m | 52,752 | 1,860 | 2,836.4% | |
Fx outflow | Rs m | 14,504 | 25 | 58,272.4% | |
Net fx | Rs m | 38,248 | 1,835 | 2,084.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 1,719 | 1,457.7% | |
From Investments | Rs m | -10,123 | -3,148 | 321.5% | |
From Financial Activity | Rs m | -10,942 | 1,426 | -767.3% | |
Net Cashflow | Rs m | 3,989 | -3 | -117,323.5% |
Indian Promoters | % | 74.8 | 33.9 | 220.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 0.0 | - | |
FIIs | % | 5.9 | 9.9 | 59.6% | |
ADR/GDR | % | 0.0 | 16.9 | - | |
Free float | % | 11.0 | 39.3 | 28.0% | |
Shareholders | 44,069 | 21,482 | 205.1% | ||
Pledged promoter(s) holding | % | 0.0 | 55.9 | - |
Compare CADILA HEALTHCARE With: PIRAMAL ENTERPRISES NOVARTIS DR. DATSONS LABS PROCTER & GAMBLE HEALTH GSK PHARMA
Compare CADILA HEALTHCARE With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More